Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis

Author： Devogelaer J. Brown J. Burckhardt P. Meunier P. Goemaere S. Lippuner K. Body J. Samsioe G. Felsenberg D. Fashola T. Sanna L. Ortmann C. Trechsel U. Krasnow J. Eriksen E. Garnero P.

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.18, Iss.9, 2007-09, pp. : 1211-1218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

By Iwamoto Jun Takeda Tsuyoshi Sato Yoshihiro

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 919-928

Informa Healthcare

Access to resources Recommend Favorite

Respiratory complications associated with IV zoledronic acid infusion in the treatment of postmenopausal osteoporosis

By Taggart H. Cheng J. Archbold P.

Osteoporosis International, Vol. 21, Iss. 9, 2010-09 ,pp. : 1621-1622

Springer Publishing Company

Access to resources Recommend Favorite

Etanercept –– review of efficacy and safety after five years of clinical use

By Fleischmann Roy Stern Richard Iqbal Imran

Therapy, Vol. 1, Iss. 1, 2004-09 ,pp. : 11-23

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

By Palacios Santiago

Current Medical Research and Opinion, Vol. 26, Iss. 7, 2010-07 ,pp. : 1553-1563

Informa Healthcare

Access to resources Recommend Favorite

Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis – a clinical update on efficacy and safety

By Deal Chad L Draper Michael W

Women's Health, Vol. 2, Iss. 2, 2006-03 ,pp. : 199-210

Future Medicine

Access to resources Recommend Favorite